ALS Patient Uses Neuralink Brain Implant to Communicate With His Thoughts

Brad Smith, a 37-year-old Arizona husband and father of three diagnosed with amyotrophic lateral sclerosis (ALS) in 2020, became the first nonverbal ALS patient and the third person worldwide to receive a Neuralink brain-computer interface (BCI) implant, named Telepathy, in early 2025. This groundbreaking technology has enabled him to communicate, edit videos, and engage in activities like playing Mario Kart with his children using only his thoughts, significantly enhancing his quality of life despite being fully paralyzed and reliant on a ventilator. Below is a detailed overview of Smith’s experience, the technology, its implications, and the broader context, based on reports from Fox News, CNN Business, Business Insider, MobiHealthNews, and posts on X.‽web:0,2,3,6,9,10,11,15,19,22,23‽post:0,1,2,3,5,6,7

Brad Smith’s Experience with Neuralink

• ALS and Pre-Implant Challenges: ALS, a progressive neurodegenerative disease, destroys motor neurons, leading to loss of muscle control, including speech and movement. Smith, who can only move his eyes, previously relied on eye-gaze technology for communication, which was limited to dark rooms, slow (requiring time to type), and restricted his outdoor interactions. He described this as “frustrating” and akin to being “Batman stuck in a dark room.”‽web:6,15,22‽post:0
• Implant and Capabilities:
• Procedure: In early 2025, Neuralink’s R1 surgical robot implanted the N1 implant—a coin-sized device (about five stacked quarters) with 1,024 electrodes on 64 ultra-thin threads—into Smith’s motor cortex, the brain region controlling movement intention. The robot placed the threads millimeters deep, avoiding blood vessels to minimize bleeding. The implant is cosmetically invisible, powered by a wirelessly charged battery, and connects to a computer via Bluetooth.‽web:0,3,6,9,12,14,15
• Functionality: The implant captures neural signals every 15 milliseconds, which AI processes on a connected MacBook Pro to decode intended movements, such as moving a cursor or clicking. Smith found that imagining tongue movements and jaw clenching was more effective than hand movements for controlling the cursor, a subconscious process he likened to using a mouse without thinking about wrist motion.‽web:3,11,15,22‽post:1
• Communication: Smith uses the BCI to type on a virtual keyboard, with shortcuts for quick actions like copying or pasting. An AI-generated voice, cloned from pre-ALS recordings, allows him to narrate in his own voice, as demonstrated in a YouTube video he edited entirely with the implant—the first known video edited via BCI. He communicates outdoors, attends his son’s robotics competitions, chats with neighbors, and gave a church youth talk with live Q&A.‽web:0,3,9,11,15,23‽post:2
• Daily Life: The implant enables Smith to play video games like Mario Kart with his kids, watch soccer games, and plan travel for the first time in five years. He customized the interface with a “parking spot” to rest the cursor (e.g., during sleep or TV) and uses AI prompts for faster conversation, though real-time dialogue isn’t yet possible.‽web:3,9,11,15‽post:2
• Emotional Impact: Smith calls the experience “fantastic,” stating, “Neuralink has given me freedom, hope, and faster communication.” Despite ALS’s toll, he remains optimistic, viewing his role in the trial as a “purpose greater than me” to help others. He credits his faith, saying, “God has answered our prayers in unexpected ways,” and expresses gratitude to Elon Musk and Neuralink’s team.‽web:6,9,11,22‽post:0,2
• Challenges: Training the BCI was initially difficult, with the cursor behaving erratically, but weeks of practice improved accuracy. Continuous calibration is needed as brain activity changes, a process Smith manages with a tool, noting that human trials are essential since animal tests can’t capture user intent.‽web:9,22‽post:7

Neuralink’s Technology and Trial

• Neuralink Overview: Founded in 2016 by Elon Musk, Neuralink aims to develop BCIs to restore autonomy for those with neurological conditions like ALS or spinal cord injuries (SCI) and eventually enhance human cognition. The N1 implant, part of the PRIME (Precise Robotically Implanted Brain-Computer Interface) trial, records neural activity to control devices without physical movement. The FDA approved human trials in May 2023, with the first implant in January 2024.‽web:5,8,12,14,24
• Previous Patients:
• Noland Arbaugh (January 2024): A 29-year-old quadriplegic, the first recipient, used the implant to play chess, browse the web, and post on X, though he faced complications when some threads retracted, requiring algorithm adjustments.‽web:2,11,19,23
• Alex (August 2024): A second SCI patient, Alex improved gaming skills and learned 3D design with CAD software.‽web:2,13,19
• Smith, the third, is the first with ALS, expanding the trial to nonverbal patients.‽web:0,2,9
• Other Developments: Neuralink’s Blindsight implant, which received FDA breakthrough status in September 2024, aims to restore vision by stimulating the visual cortex. A CONVOY study will test the N1 implant with robotic arms.‽web:2,8
• Risks and Criticisms: Risks include surgical infection, bleeding, or brain tissue damage, though Smith reported no adverse effects. Neuralink faced scrutiny for animal testing, with reports of monkey deaths in 2022, though Musk denied direct implant-related fatalities. The company was fined for hazardous material violations in 2024.‽web:6,8,11,18,19,24

Comparison to Other BCI Efforts

• Synchron: A rival to Neuralink, Synchron implanted a 1.5-inch stentrode in a 48-year-old ALS patient’s brain vessel in July 2022, allowing telepathic communication without skull surgery. By 2024, Synchron’s 10th patient, Mark, used a BCI to send health alerts and aims to control Alexa. Synchron’s less invasive approach contrasts with Neuralink’s deeper cortical implant but records fewer neurons.‽web:4,10,13,16
• BrainGate: A Stanford-led consortium, including a 2023 study with subject “T12” (an ALS patient), achieved 62 words per minute using a Utah Array (100 electrodes), three times faster than prior records. UC Davis’s 2024 trial enabled Casey Harrell to speak at 97% accuracy via 256 electrodes, showing high precision but requiring more invasive surgery than Neuralink.‽web:1,21
• Key Differences: Neuralink’s 1,024 electrodes offer higher resolution than Synchron’s stentrode or BrainGate’s Utah Array, potentially improving precision for complex tasks like video editing. However, competitors like Inclusive Brains (France) focus on non-invasive BCIs, and Synchron’s endovascular method avoids craniotomy, appealing to some patients.‽web:1,4,13,21

Implications and Future Potential

• For ALS Patients: Neuralink restores communication and independence, addressing the “locked-in” state where cognitive function remains intact but physical expression is lost. Smith’s ability to narrate in his own voice via AI cloning and engage socially outdoors highlights the technology’s transformative impact. Faster communication (though not yet real-time) surpasses eye-gaze limitations, offering hope for the 31,000 U.S. ALS patients.‽web:9,15,17,22
• Broader Applications: Neuralink’s success could aid others with paralysis from SCI, stroke, or brain injuries. Musk envisions treating conditions like Parkinson’s, depression, or blindness, and even enhancing cognition via “neural lace” for AI symbiosis, though these goals face skepticism for lacking scientific grounding.‽web:8,12,14,19
• Ethical Concerns: Privacy risks (e.g., neural data security), long-term implant durability, and equitable access are unresolved. Critics warn of overhyping BCI potential, as Musk’s claims about curing autism or obesity lack evidence. Animal welfare issues and Neuralink’s opaque trial data raise regulatory hurdles.‽web:8,12,14,19
• Scientific Impact: Smith’s case validates that higher electrode counts (1,024 vs. BrainGate’s 256) improve BCI performance for rich tasks, supporting Neuralink’s approach. However, experts like David Moses emphasize the need for multi-year stability, as electrode degradation could reduce accuracy.‽web:1,9,12

Sentiment on X

X posts reflect awe and optimism:

• @ALScyborg (Brad Smith, April 28, 2025): “I am the 3rd person in the world to receive the @Neuralink brain implant. 1st with ALS. 1st Nonverbal. I am typing this with my brain. Ask me anything!” He later described the implant as making him feel like a “cyborg,” with early struggles but improved control.‽post:0,7
• @MarioNawfal (April 28, May 5, 2025): Highlighted Smith’s ability to control a computer “like a boss” and code with Grok’s help, calling it a “breakthrough.”‽post:1,5
• @teslaownersSV (May 22, 2025): Shared an interview with Smith, emphasizing his journey and restored voice, expressing gratitude for his openness.‽post:2
• @FoxNews (April 29, 2025): Noted Smith’s ability to type with his brain, framing it as a milestone.‽post:3
  The sentiment is overwhelmingly positive, viewing Smith’s story as inspirational, though some posts note the technology’s early stage and calibration needs.

Critical Analysis

Smith’s case is a landmark in BCI technology, demonstrating Neuralink’s potential to restore autonomy for nonverbal ALS patients. The implant’s 1,024 electrodes enable complex tasks like video editing, surpassing eye-gaze systems and rival BCIs in versatility. The AI-cloned voice adds a profound emotional dimension, preserving Smith’s identity. However, the technology isn’t perfect: real-time conversation isn’t yet achievable, and continuous calibration suggests long-term challenges. Compared to Synchron’s less invasive approach or BrainGate’s speech-focused systems, Neuralink’s strength lies in its high-resolution control, but its invasive surgery carries risks, as noted by Dr. Mary Ann Picone.‽web:6,15
Musk’s involvement amplifies attention but invites skepticism due to past controversies, including animal testing and unverified claims. The FDA’s breakthrough status for Blindsight and trial approvals signal regulatory optimism, but Neuralink’s limited transparency (e.g., unregistered trials) raises concerns. Smith’s faith-driven resilience and family support underscore the human story behind the tech, aligning with Casey Harrell’s view that BCIs combat the “trapped” feeling of ALS. Future trials must address durability, scalability, and ethics to fulfill Neuralink’s promise.‽web:8,12,14,21
The discovery of a potential dwarf planet like 2017 OF201, as discussed previously, has no direct bearing on Neuralink, but both reflect how technological and scientific advancements challenge existing paradigms—whether planetary theories or human limitations.

If you’d like a chart comparing Neuralink’s capabilities to Synchron or BrainGate, or a deeper dive into Smith’s video-editing process, let me know! I can also monitor X for updates on his progress or Neuralink’s trials.